SPECIAL NOTICE
99 -- Serological Sciences Network Capacity Building Centers; Special Notice of Subcontract Opportunity at the Frederick National Laboratory for Cancer Research
- Notice Date
- 6/18/2020 8:42:14 AM
- Notice Type
- Special Notice
- NAICS
- 541715
— Research and Development in the Physical, Engineering, and Life Sciences (except Nanotechnology and Biotechnology)
- Contracting Office
- NIH National Cancer Institute Rockville MD 20850 USA
- ZIP Code
- 20850
- Solicitation Number
- S20-119
- Response Due
- 7/16/2020 9:00:00 AM
- Archive Date
- 07/31/2020
- Point of Contact
- Heather Sewell, Senior Subcontracts Administrator
- E-Mail Address
-
NCIFSSN@nih.gov
(NCIFSSN@nih.gov)
- Description
- National Institutes of Health, National Cancer Institute, Frederick National Laboratory for Cancer Research Opportunities-Special Announcements: This Special Notice is not a formal Invitation for Bid (IFB), Request for Proposal (RFP), Request for Quotation (RFQ) nor any type of solicitation for offers. In accordance with FAR 15.201(d), this special notice is intended FOR INFORMATIONAL PURPOSES ONLY in order to: 1) publicize the requirements of the Frederick National Laboratory for Cancer Research (FNLCR); and 2) increase participation by qualified HUBZone small business, small, small disadvantaged, women-owned small business, veteran-owned small business and service-disabled veteran-owned small business concerns, as applicable. The FNLCR is a Government-Owned Contractor-Operated (GOCO) Federally Funded Research and Development Center (FFRDC) located at Fort Detrick, Maryland. The FNLCR partners with university, government, and corporate scientists to speed the translation of laboratory research into new diagnostic tests and treatments for cancer and AIDS. FNLCR is a multi-program laboratory currently operated by Leidos Biomedical Research Inc. for the National Cancer Institute (NCI) under Prime Contract No. 75N91019D00024, which provides Operations and Technical Support (OTS) for the Frederick National Lab. The Government assumes no liability for reimbursement for any effort or associated costs to respond, nor for any information provided as a result of this notice as no information is being requested. Please be advised that any submissions provided despite the aforementioned notice that no information is requested become Government property and will not be returned, nor will there be any ensuing discussions or debriefings of any responses. Responses submitted to this notice are not offers and cannot be accepted by the U.S. Government to form a binding contract. It is the responsibility of the interested parties to monitor this site and any sites referenced herein for additional information pertaining to business opportunities with the FNLCR, if any. Serological Sciences Network Project Background and Objectives:������� �Background A.1.������ General In light of the emergence of the novel coronavirus, Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2), and the urgent need to mitigate the pathogen�s spread, the National Cancer Institute (NCI) and the National Institute of Allergy and Infectious Disease (NIAID) are establishing a Serological Sciences Network of Excellence to mobilize collaborative efforts to develop serological assays of high specificity and high sensitivity for deployment to test for SARS-CoV-2 induced immune responses and to rapidly expand national serological testing capacity. The proposed Serological Sciences Network for SARS-CoV-2 (SeroNet) will contain several components.� The Serological Capacity Building Centers are a critical component of the SeroNet. The Capacity Building Centers (CBC) shall focus on the rapid deployment and expansion of SARS-CoV-2 serological testing capacity and practice. In addition to the CBCs, the SeroNet includes the Centers of Excellence, Research Projects, and the Frederick National Laboratory for Cancer Research (FNLCR) Serology Laboratory.� Serological Sciences Centers of Excellence and Serological Sciences Research Projects will be grant funded to understand the mechanisms driving serological, humoral, and cellular immune responses to SARS-CoV-2 viral infection to inform the development of novel serological tests. Each SeroNet component is expected to interact closely, collaborate, share data, resources, and samples. The Serological Sciences Network Coordinating Center (SSNCC) at FNLCR will manage and coordinate data and communications across SeroNet, and a Steering Committee comprised of members from each component, including NCI and NIAID, will provide scientific oversight and guidance. A.2.������ Project Background The lack of validated and standardized tests, procedures, reagents, and capabilities for the assessment of SARS-CoV-2-specific antibody responses represent critical gaps in the national infrastructure. To address these critical gaps, key stakeholders with interest and expertise in serological assay development and implementation will work collaboratively to standardize, harmonize and expand capacity for serological testing for SARS-CoV-2. Development of serological assays require standards, positive and negative controls along with proficiency panel samples. Serological assays are a critical tool for determining prevalence of infection and immune responses to the virus and vaccines. Serological assays include ELISAs, point of care lateral flow tests, and virus neutralization assays. Highly reproducible, high-throughput serological assays with high sensitivity and high specificity are urgently needed. � � � � �� Objectives The objective is to address unmet needs in SARS-CoV-2 serological testing: 1) standardization, 2) assay development, and 3) availability of large-scale testing to identify those who may have been infected or exposed to the virus. Scaling up of validated SARS-CoV-2 serological assays with Emergency Use Authorization (EUA) with evidence of high specificity, sensitivity and reproducibility, will increase not only the national testing capacity, but also enable comparisons of data across different sites and studies. Therefore, it will facilitate an understanding of natural history of the SARS-CoV-2 infection, vaccine development, and implementation of new vaccine candidates. This work will be conducted in partnership with SeroNet (academic and commercial serology laboratories), including the FNLCR Serology Laboratory, SSNCC and the SSC, to develop and make available reagents and standards to the serology community once generated and qualified. Leidos Biomedical Research, Inc. POC:��� For a copy of Solicitation S20-119, please contact: Heather Sewell, Senior Subcontracts Administrator, at: NCIFSSN@nih.gov� For information concerning other opportunities with the FNLCR, please refer to: https://frederick.cancer.gov/workwithus/solicitations
- Web Link
-
SAM.gov Permalink
(https://beta.sam.gov/opp/3a5dde333b694c28a58a323df54879da/view)
- Record
- SN05695275-F 20200620/200618230156 (samdaily.us)
- Source
-
SAM.gov Link to This Notice
(may not be valid after Archive Date)
| FSG Index | This Issue's Index | Today's SAM Daily Index Page |